Join our Community
Support ToI and remove all ads
Learn more

ISRAEL AT WAR - DAY 570

Sanofi

A Teva Pharmaceuticals logistics center in Shoham, January 7, 2021. (Yossi Aloni/ Flash90)
December 17, 2024, 11:51 pm
Teva soars on ‘positive’ trial results for inflammatory bowel disease treatment
Patients treated with antibody ‘duvakitug,’ jointly developed with French drug-maker Sanofi, achieved a higher rate of clinical remission
By Sharon Wrobel
CytoReason co-founders from right to left: David Harel, CEO, Professor Shai Shen-Orr, chief scientist, Elina Starosvetsky, VP biology, and Renaud Gaujoux, principal scientist and data science architect. (Fabian Koldorff)
July 17, 2024, 9:50 pm
Backed by Nvidia and Pfizer, Israeli AI medical startup raises $80m in fresh capital
Tel Aviv-based CytoReason, which uses machine learning to build computational models of human diseases to speed up treatment discoveries, plans to open a US office later this year
By Sharon Wrobel
Illustrative: Vaccination in Rehovot, January 10, 2022 (Yossi Aloni/Flash90)
July 6, 2023, 5:59 pm
Sheba Pandemic Research Institute and partners developing pan-coronavirus vaccine
Researchers apply AI to unique database of healthcare workers’ blood samples to determine best antigen to protect against multiple pathogens and variants
By Renee Ghert-Zand
CytoReason co-founders from right to left: David Harel, CEO; Prof. Shai Shen-Orr, chief scientist; Elina Starosvetsky, VP Biology; Renaud Gaujoux, principal scientist and data science architect. (Fabian Koldorff)
January 24, 2023, 9:02 pm
Sanofi extends cooperation with Israel’s CytoReason for bowel disease drug discovery
Tel Aviv-based startup that uses AI to build digital models of the human immune system and diseases inks multi-million-dollar deal with French drugmaker
By Sharon Wrobel
Workers in the Biond Biologics lab in Misgav, Israel (Courtesy)
January 27, 2021, 11:45 am
Sanofi’s $125 million Israeli drug buy could be a three-pronged cancer buster
Biond Biologics hopes its therapy, which activates 3 separate immune pathways, will prove to be ‘strong and sustained anti-tumor response,’ says CEO; human trials to start mid-2021
By Shoshanna Solomon
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.